Benjamin Miller

1.3k total citations
23 papers, 1.1k citations indexed

About

Benjamin Miller is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, Benjamin Miller has authored 23 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pharmacology, 12 papers in Molecular Medicine and 11 papers in Epidemiology. Recurrent topics in Benjamin Miller's work include Antibiotic Resistance in Bacteria (12 papers), Antibiotics Pharmacokinetics and Efficacy (12 papers) and Urinary Tract Infections Management (6 papers). Benjamin Miller is often cited by papers focused on Antibiotic Resistance in Bacteria (12 papers), Antibiotics Pharmacokinetics and Efficacy (12 papers) and Urinary Tract Infections Management (6 papers). Benjamin Miller collaborates with scholars based in United States, Switzerland and Australia. Benjamin Miller's co-authors include Ellie Hershberger, Ian R. Friedland, Judith N. Steenbergen, Myra W. Popejoy, Joseph S. Solomkin, Jennifer A. Huntington, Alicia R Desilets, Alan Xiao, Kristine C. Willett and David P. Nicolau and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and The American Journal of Gastroenterology.

In The Last Decade

Benjamin Miller

22 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Benjamin Miller United States 11 700 651 382 325 70 23 1.1k
A. Boillot France 14 158 0.2× 61 0.1× 162 0.4× 115 0.4× 48 0.7× 27 666
Shian‐Sen Shie Taiwan 16 94 0.1× 49 0.1× 129 0.3× 35 0.1× 57 0.8× 42 653
Jitender Sethi United States 5 201 0.3× 104 0.2× 51 0.1× 52 0.2× 26 0.4× 8 406
Ibrahim Alzahrani Saudi Arabia 12 163 0.2× 39 0.1× 51 0.1× 59 0.2× 51 0.7× 45 408
C. Fendri Tunisia 14 138 0.2× 31 0.0× 126 0.3× 30 0.1× 35 0.5× 46 568
Jean‐Daniel Graf Switzerland 11 14 0.0× 29 0.0× 431 1.1× 90 0.3× 71 1.0× 14 861
M L McFadyen South Africa 11 106 0.2× 66 0.1× 27 0.1× 15 0.0× 17 0.2× 18 385
P. Lutun France 12 15 0.0× 47 0.1× 376 1.0× 37 0.1× 42 0.6× 24 674
L. Minicucci Italy 15 69 0.1× 27 0.0× 62 0.2× 11 0.0× 17 0.2× 39 562
Aimin Guo China 8 15 0.0× 19 0.0× 102 0.3× 59 0.2× 17 0.2× 23 425

Countries citing papers authored by Benjamin Miller

Since Specialization
Citations

This map shows the geographic impact of Benjamin Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Miller more than expected).

Fields of papers citing papers by Benjamin Miller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Miller. The network helps show where Benjamin Miller may publish in the future.

Co-authorship network of co-authors of Benjamin Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Miller. A scholar is included among the top collaborators of Benjamin Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Miller. Benjamin Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Allegretti, Jessica R., Adam S. Cheifetz, Parambir S. Dulai, et al.. (2024). Safety, Pharmacokinetics, and Clinical Efficacy of ADS051, a Neutrophil Modulator, in Ulcerative Colitis: Results of a Randomized Phase 1b Trial. The American Journal of Gastroenterology. 120(7). 1624–1635. 1 indexed citations
2.
Cheifetz, Adam S., Jessica R. Allegretti, Bharat L. Dixit, et al.. (2024). Small-Molecule Neutrophil Modulator ADS051 is Safe and Well-Tolerated in a Phase 1 Single Ascending Dose Study. The American Journal of Gastroenterology. 120(7). 1585–1592. 1 indexed citations
3.
Niemiller, Matthew L., et al.. (2023). Fern Cave: A Hotspot of Subterranean Biodiversity in the Interior Low Plateau Karst Region of Alabama in the Southeastern United States. Diversity. 15(5). 633–633. 5 indexed citations
4.
Niemiller, Matthew L., et al.. (2019). Discovery of a new population of the federally endangered Alabama Cave Shrimp, Palaemonias alabamae Smalley, 1961, in northern Alabama. Subterranean Biology. 32. 43–59. 3 indexed citations
5.
6.
7.
Popejoy, Myra W., David L. Paterson, Daniel Cloutier, et al.. (2016). Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trials. Journal of Antimicrobial Chemotherapy. 72(1). 268–272. 95 indexed citations
8.
Miller, Benjamin, Myra W. Popejoy, Ellie Hershberger, Judith N. Steenbergen, & John C. Alverdy. (2016). Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study. Antimicrobial Agents and Chemotherapy. 60(7). 4387–4390. 29 indexed citations
9.
Miller, Benjamin, et al.. (2016). Pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Japanese, Chinese, and white subjects. Fundamental and Clinical Pharmacology. 30(6). 625–633. 11 indexed citations
10.
Prabhu, Vimalanand S., Saugata Sen, Benjamin Miller, Anirban Basu, & Goran Medić. (2015). Using An Economic Model To Choose Initial Appropriate Antibiotic Therapy Based On Differences In In-Vitro Susceptibility To Ceftolozane/Tazobactam And Piperacillin/Tazobactam. Value in Health. 18(7). A536–A536. 1 indexed citations
11.
Solomkin, Joseph S., Ellie Hershberger, Benjamin Miller, et al.. (2015). Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Clinical Infectious Diseases. 60(10). 1462–1471. 311 indexed citations
12.
Popejoy, Myra W., Eliana S. Armstrong, Benjamin Miller, et al.. (2015). Clinical Outcomes of Ceftolozane/Tazobactam Treatment of Piperacillin/Tazobactam and Ceftazidime Non-Susceptible Pathogens From Two Phase 3 Trials and Associated in Vitro Activity. Open Forum Infectious Diseases. 2(suppl_1). 1 indexed citations
13.
Lucasti, Christopher, Ellie Hershberger, Benjamin Miller, et al.. (2014). Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections. Antimicrobial Agents and Chemotherapy. 58(9). 5350–5357. 93 indexed citations
14.
Popejoy, Myra W., Daniel Cloutier, Judith N. Steenbergen, et al.. (2014). 260Ceftolozane/Tazobactam for the Treatment of cUTI and cIAI Caused by ESBL-producing Enterobacteriaceae. Open Forum Infectious Diseases. 1(suppl_1). S111–S111. 1 indexed citations
15.
Miller, Benjamin, Myra W. Popejoy, Ellie Hershberger, et al.. (2014). 251Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Phase 3 Ceftolozane/Tazobactam Study. Open Forum Infectious Diseases. 1(suppl_1). S108–S108. 1 indexed citations
16.
Miller, Benjamin, et al.. (2012). Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses. Antimicrobial Agents and Chemotherapy. 56(6). 3086–3091. 106 indexed citations
17.
Miller, Benjamin, Kristine C. Willett, & Alicia R Desilets. (2011). Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease. Annals of Pharmacotherapy. 45(11). 1416–1424. 100 indexed citations
18.
Rich, Peter, Anthony LaMarca, Keith H. Loven, et al.. (2001). Safety and efficacy of short-duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetes.. PubMed. 68(1 Suppl). 15–22. 4 indexed citations
19.
Box, Hilary O., et al.. (1998). Prairie Night: Black-Footed Ferrets and the Recovery of Endangered Species. Journal of Wildlife Management. 62(3). 1156–1156. 83 indexed citations
20.
Miller, Benjamin, et al.. (1970). A Method Of Tagging Large Aquatic Beetles. Entomological News. 81. 253–256. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Boillot Breakdown of academic impact, for papers by Shian‐Sen Shie Breakdown of academic impact, for papers by Jitender Sethi Breakdown of academic impact, for papers by Ibrahim Alzahrani Breakdown of academic impact, for papers by C. Fendri Breakdown of academic impact, for papers by Jean‐Daniel Graf Breakdown of academic impact, for papers by M L McFadyen Breakdown of academic impact, for papers by P. Lutun Breakdown of academic impact, for papers by L. Minicucci Breakdown of academic impact, for papers by Aimin Guo
Rankless by CCL
2026